BTK inhibitors reportedly synergize with 5-FU to treat drug-resistant TP53-null colon cancers, and using BTK inhibitors in combination with 5-FU is a novel therapeutic approach for colorectal cancer [27]. This evidence concerns the gene BTK and malignant colon neoplasm.